P3781
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse TreatmentPXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By SurgeryA Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, MalignanciesSafety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung CancerBelinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic SyndromeBelinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown PrimaryBelinostat in Relapsed or Refractory Peripheral T-Cell LymphomaA Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological MalignanciesMaximum Tolerated Dose Study of Belinostat (PXD-101)in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerPevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeBelinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic DysfunctionPhase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaBelinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHLA Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung CancerBelinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or CisplatinA Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced CancersA Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue SarcomasTrial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive TherapyBelinostat (PXD101) to Treat Tumors of the Thymus at an Advanced StageA Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell LymphomaMRSI to Predict Response to RT/TMZ ± Belinostat in GBMA Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple MyelomaStudy of Oral PXD101 in Patients With Advanced Solid Tumors or LymphomaStudy of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid TumorsPXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaBelinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesPXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasBelinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by SurgeryBelinostat in Treating Patients With Liver Cancer That Cannot Be Removed By SurgeryBelinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed LymphomaTo Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 GenotypesTo Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaBelinostat in Treating Patients With Myelodysplastic SyndromesPXD101 in Treating Patients With Acute Myeloid LeukemiaBelinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential TumorsA Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell LymphomasClinical Trial of PXD101 in Patients With Advanced Multiple MyelomaStudy of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
P4844
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivoA phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.Drug monographs: belinostat and idelalisib.A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasmaLong-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.Belinostat for the treatment of peripheral T-cell lymphomas.Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.PXD101 significantly improves nuclear reprogramming and the in vitro developmental competence of porcine SCNT embryos.Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRIBelinostat: first global approval
P921
Q21154358-8F2F77E5-2E5A-4A8F-9C6E-A5D109667F08Q21173206-A13CCA90-872B-4380-8ADF-EB750C4F8667Q21173207-07974BB4-9D58-42A4-8705-013FC0528CC6Q21173381-8D115179-498C-45B0-B5DC-B2D8390F0C67Q21173406-4EAF5DF2-4015-486A-8ACA-620C408E99A7Q21173427-3A3255F7-173F-48F7-92D9-FDA0C841E7B4Q5629167-68119C06-95B6-4BD3-A8D3-F21C4299ABC6Q5773155-11A8D6F3-0B2A-4B7A-97E9-8E8DAFAE15C7Q5773160-31D27285-52AA-4D59-8225-A5D96DFEB8CB
P129
Q61921830-9AF8F390-188E-400C-8219-66899B44ED6CQ61934396-5793BE37-5EC0-41B9-85CB-F430ED0C989CQ61936060-F9D2BF0F-89F1-43C0-866C-80457C923D7CQ61937143-8164D67B-7C09-4A81-B9B9-31516269A564Q61938238-720A32D3-B966-4677-925F-D14355BACAEBQ61980423-2DBD3D90-2689-4153-B0D2-73287BCBE2FEQ61981025-AB91F50E-A44E-467E-B4E3-F827E1E75960Q63337542-386085DA-EFAF-460D-AAEB-A20712B3AAF5Q63339353-5925E70F-D08E-414A-AAF9-19A4C0B2CE7CQ63403601-24225C93-985B-4867-AECD-5C02620E7284Q63572954-97CB0801-E83C-4B0B-870E-A10CEC88AC87Q63815534-805ADDCC-2ED7-43C0-847A-AEB7059EEA9DQ64398216-F9B07B3E-0EA9-4F0E-B7E3-5AB866E48663Q64641452-F5082B85-4C23-48B0-BCC0-90539EF77341Q64653070-6F85D6C0-3E5A-4E59-BF17-54195C97CE3AQ64661096-E543100A-7A69-411F-957E-FC7415DF8FC3Q64674050-C0B800EA-0088-4402-8A4B-C1E81C3B7A32Q64680100-04ACCFC0-B188-491D-A199-A56951A8AEA5Q64680113-C94CD39B-637A-4F1A-B14B-E9E8C9110074Q64725551-CEC4D151-F323-4A43-96A5-EC92FF927C44Q65335161-CCA95886-900D-4211-B71B-EAC679F6B228Q65358320-167A23F6-AA5B-4DEF-A10A-24F57D29C24AQ65384227-BD5FEAC9-CBF3-451C-8620-D656FE9B56FFQ65384938-6E9D0280-D851-484E-A80F-87833FE03251Q65384960-5B6A5752-0A40-4613-82DF-EB11ADA2F875Q65387342-90E86237-C6CA-450B-B9D2-E78312F39A7FQ65387745-50D4BBE5-F61A-41FE-98E6-B544851D5118Q65388329-3C22BC5D-BB58-4326-AA55-FCC63ECCC71FQ65390117-631BFB20-B882-4A67-86A2-B6C0C061A4A6Q65390124-C4A07E03-AD8B-4404-9B24-C70991EB4E3DQ65399470-EA18DE1C-24D3-4BB2-BC4E-5D92803C1451Q65399584-8DFEDE00-A844-4633-80D2-E4FFE7D98AE9Q65400572-83F7B626-2F06-466F-9B35-8CFEDEEF1644Q65474997-EE29C54B-5D17-481F-8E66-425E8EF9A12BQ65475283-BB88AAB4-88A7-4451-A2FC-E0B72EC3FE25Q65475307-179C990C-CC4C-4889-B14D-20ED3F896779Q65475431-F3797973-18B3-40EF-A83F-C47390D481BEQ65539384-FE2BB909-9744-447E-B7FC-2222ECE49423Q66030440-BF8FFD78-36CF-4082-AB33-EB59FD165B74Q66083375-82CFAEEF-B32D-4D31-8C89-D07AF0F7B12F
P4844
Q33417499-A7E7803A-45A4-4A55-8E94-3A28DFEA09F7Q33418737-D02DCBF6-C3DB-42B6-93B3-6FDE0317F9C7Q33927370-0F9EFB5D-5818-4A80-BD7E-AE394C03A408Q34084575-F0F33E40-A5EB-4DE9-9742-00CF50383300Q34434810-8170FA10-BC63-4BF9-97AD-E8174E50ADDBQ34575453-7303815F-2076-4306-9B51-DC7B6F175894Q35057942-6F134DB1-85AF-446F-BC17-8905EF6A6F4CQ35327711-DCF4A403-3B14-4514-A45A-6515D5D3C988Q36874638-4BBED3FA-1BBA-435A-97AE-A401E525306AQ37355651-9B26712B-72DD-49D8-A114-A695119F23C0Q38219494-9857559F-9095-463F-8694-86F0A4C96E42Q38941054-73A9E401-E105-4629-BACB-E8937D4BAB9AQ38998021-E59ED71B-236E-4AE6-A092-151CE23A0482Q39051716-AAFBADD0-C46D-491F-A758-FA1F5ABAEB35Q46809218-D3D4B9C3-0B31-4AF5-872B-48801C74A555Q48590230-8D7D9BEE-C5C8-4205-9625-75CDB97EC71BQ64085069-A74AE6D8-C6C2-4DC8-B571-50E7F6260A01Q87609508-D4B63924-1027-47E0-B6CA-D190F6DB6733
P921
description
chemická sloučenina
@cs
chemische Verbindung
@de
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
composé chimique
@fr
name
Belinostat
@en
Belinostat
@sh
Belinostat
@sr
Belinostat
@vi
Белиностат
@ru
貝利司他
@zh
type
label
Belinostat
@en
Belinostat
@sh
Belinostat
@sr
Belinostat
@vi
Белиностат
@ru
貝利司他
@zh
altLabel
PXD-101
@en
prefLabel
Belinostat
@en
Belinostat
@sh
Belinostat
@sr
Belinostat
@vi
Белиностат
@ru
貝利司他
@zh
P129
P31
P486
P592
P6366
P661
P662
P683
P117
P129
P1748
P2017
ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC2=CC=CC=C2
P2067
318.067428
P2115
N0000190861
P2275
Belinostat
@en